| Literature DB >> 22795229 |
F Y F L De Vos1, H W M van Laarhoven, J S E Laven, A P N Themmen, L V A M Beex, C G J Sweep, C Seynaeve, A Jager.
Abstract
Breast cancer is the most common malignancy amongst women in the developed world. For patients with hormone-sensitive breast cancer eligible for adjuvant hormonal therapy, it is important to know if the ovaries are (still) functional or not. Indeed, the choice for a specific adjuvant hormonal treatment depends on the menopausal status of an individual woman. The currently available measures to determine the menopausal status are conflicting. Until better measures become available, we propose a practical guideline enabling an optimal choice of adjuvant hormonal therapy for women with a hormone receptor positive breast cancer taking into account uncertainties about their menopausal status.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22795229 DOI： 10.1016/j.critrevonc.2012.06.005
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312